Bioasis and Chiesi Group to Host Webcast on July 16, 2020

BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB^{3 TM} platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare genetic diseases, brain cancers, neurodegenerative diseases and pain, and Chiesi Global Rare Diseases, a business unit of Chiesi Group, an international research-focused healthcare Group, today announced that the companies will host a webcast presentation and conference call at 1:30 p.m. EDT on Thursday, July 16, 2020 to discuss the previously announced Rare Diseases Strategic Alliance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005977/en/

On June 29, 2020 Bioasis and Chiesi Global Rare Diseases announced that they entered into a worldwide, exclusive licensing agreement for the xB³ BBB platform technology in treatment of rare diseases with a focus on four undisclosed lysosomal storage disorders (“LSDs”).

Under the terms of the Research Collaboration and License Agreement (the “Agreement”), Chiesi Group will pay Bioasis an upfront payment of US$3 million. Bioasis may also be eligible to receive additional development, regulatory and commercial milestone payments of up to US$138 million, as well as additional royalties on net sales of licensed products, pending market approval. Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.

For those wishing to join the July 16th event, it is highly recommended to access the webcast over the internet using the following link. A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.

If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or [phone] (International Toll). Callers should dial-in 5-10 minutes prior to the scheduled start time and simply ask to join the call. A teleconference replay will be available for two weeks following the conclusion of the event and can be accessed by dialing 1-800-319-6413 (within Canada / USA) or [phone] (International Toll) and using the replay access code: 4669.